|12 Months Ended|
Dec. 31, 2021
The Company operates in one reportable operating segment, being the development and commercialization of therapies to treat progressive kidney disease. As the operations comprise a single reporting segment, amounts disclosed also represent segment amounts. All long-term assets of the Company are located in Canada.
The disclosure of operating segments. [Refer: Operating segments [member]]
Reference 1: http://www.xbrl.org/2003/role/disclosureRef